Compare TPST & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPST | COSM |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.9M |
| IPO Year | 2012 | 2009 |
| Metric | TPST | COSM |
|---|---|---|
| Price | $0.77 | $0.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 157.6K | ★ 2.5M |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.15 |
| EPS | N/A | ★ N/A |
| Revenue | $295,000.00 | ★ $65,271,815.00 |
| Revenue This Year | N/A | $54.08 |
| Revenue Next Year | N/A | $32.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.93 |
| 52 Week Low | $0.76 | $0.16 |
| 52 Week High | $12.22 | $1.32 |
| Indicator | TPST | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 53.83 |
| Support Level | N/A | $0.17 |
| Resistance Level | $1.09 | $0.28 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 11.49 | 57.64 |
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.